Business Context and Reporting Period
This is an Amendment No. 2 to a Form 8-K filed by AdventRX Pharmaceuticals, Inc. (not Savara Inc.) on March 25, 2008, regarding events occurring on February 29, 2008, and March 24, 2008. The filing supplements Item 5.02 concerning the appointment of Eric Rowinsky, M.D., to the Board of Directors and the associated compensatory stock option grant.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific equity compensation grant:
- Option Grant: 50,000 shares of common stock.
- Exercise Price: $0.48 per share (closing price on March 24, 2008).
- Expiration Date: March 24, 2018.
Material Changes
The primary material change is the finalization of a stock option grant to Dr. Rowinsky. While the Board approved the grant on February 29, 2008, issuance was contingent upon a waiver from specific Purchasers under a Rights Agreement. On March 24, 2008, the Company received the necessary waiver, allowing the grant to proceed without triggering participation rights.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, outlook, or general risk factors. The specific contingency addressed was the requirement for a waiver under the Rights Agreement dated July 27, 2005, involving Icahn Partners LP and other entities. This contingency was resolved on March 24, 2008.
Investor Verification Checklist
- Verify the identity of the registrant as AdventRX Pharmaceuticals, Inc. (not Savara Inc.).
- Confirm the vesting schedule: 1/12 of shares vest monthly starting March 2008.
- Note the post-termination exercise window: 3 years after service termination (subject to the 2018 expiration).
- Review the 2005 Equity Incentive Plan for full terms and conditions of the grant.